Literature DB >> 14551676

Differential effects of modern immunosuppressive agents on the development of intimal hyperplasia.

Julian R Waller1, Nicholas R Brook, Gareth R Bicknell, Michael L Nicholson.   

Abstract

Modern immunosuppressive agents such as tacrolimus and rapamycin are claimed to be associated with a reduction in vascular narrowing, a central feature of chronic rejection. This study assesses the effect of cyclosporine, tacrolimus and rapamycin on the development of intimal thickening, fibrosis-associated genes and deposition of extracellular matrix (ECM) proteins in a model of intimal hyperplasia. Male Sprague-Dawley rats received either no treatment or 5 mg/kg cyclosporine, 0.1 mg/kg tacrolimus or 0.05 mg/kg rapamycin. Animals underwent left common carotid balloon angioplasty, and intima medial ratios, pro-fibrotic gene expression and ECM accumulation were calculated at 14 and 28 days. Cyclosporine was associated with increased intimal thickening compared to controls ( P < 0.004). Tacrolimus had no effect on intimal thickening, whilst rapamycin significantly inhibited intimal thickening at both 14 and 28 days ( P < 0.004 and P < 0.026, respectively). All groups significantly inhibited matrix metalloproteinase (MMP)-2, MMP-9, tissue inhibitor of metalloproteinases (TIMP)-1, transforming growth factor (TGF)-beta and collagen III expression at 14 days ( P < 0.001), but increased ECM deposition. However, rapamycin marginally reduced ECM deposition compared to cyclosporine ( P < 0.06). Treatment with cyclosporine was associated with worsening of vascular narrowing, whilst rapamycin showed a beneficial reduction in intimal thickening. Treatment with all immunosuppressive agents resulted in increased ECM deposition. Rapamycin may halt the progression of vascular narrowing compared to both cyclosporine and tacrolimus.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14551676     DOI: 10.1007/s00147-003-0653-8

Source DB:  PubMed          Journal:  Transpl Int        ISSN: 0934-0874            Impact factor:   3.782


  6 in total

Review 1.  Surgical biology for the clinician: vascular effects of immunosuppression.

Authors:  Elissa Tepperman; Danny Ramzy; Jessica Prodger; Rohit Sheshgiri; Mitesh Badiwala; Heather Ross; Vivek Raoa
Journal:  Can J Surg       Date:  2010-02       Impact factor: 2.089

Review 2.  Extracellular matrix molecules: potential targets in pharmacotherapy.

Authors:  Hannu Järveläinen; Annele Sainio; Markku Koulu; Thomas N Wight; Risto Penttinen
Journal:  Pharmacol Rev       Date:  2009-06       Impact factor: 25.468

3.  Effective treatment of advanced colorectal cancer by rapamycin and 5-FU/oxaliplatin monitored by TIMP-1.

Authors:  Markus Wagner; Vincent Roh; Michael Strehlen; Alexander Laemmle; Deborah Stroka; Bernhard Egger; Markus Trochsler; Kelly K Hunt; Daniel Candinas; Stephan A Vorburger
Journal:  J Gastrointest Surg       Date:  2009-06-30       Impact factor: 3.452

4.  Five-year follow-up after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft nephropathy.

Authors:  Sheng-Qiang Xia; Yu Fan; Ming-Yue Tan; Jun-Hua Zheng
Journal:  Int J Clin Exp Med       Date:  2015-03-15

5.  The Effect of Chronic Immunosuppressive Regimens Treatment on Aortal Media Morphology and the Balance between Matrix Metalloproteinases (mmp-2 and mmp-9) and Their Inhibitors in the Abdominal Aorta of Rats.

Authors:  Anna Surówka; Kamila Szumilas; Aleksandra Wilk; Kamila Misiakiewicz-Has; Kazimierz Ciechanowski; Karolina Kędzierska-Kapuza
Journal:  Int J Environ Res Public Health       Date:  2022-05-24       Impact factor: 4.614

6.  Effects of simultaneous pancreas-kidney transplantation and kidney transplantation alone on the outcome of peripheral vascular diseases.

Authors:  Robert Sucher; Sebastian Rademacher; Nora Jahn; Max Brunotte; Tristan Wagner; Athanasios Alvanos; Elisabeth Sucher; Daniel Seehofer; Uwe Scheuermann; Hans-Michael Hau
Journal:  BMC Nephrol       Date:  2019-12-09       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.